Promyelocytic leukemia (PML) plays a tumor suppressive role by inducing cellular senescence in response to oncogenic stress. However, tumor cell lines fail to engage in complete senescence upon PML activation. In this study, we investigated the mechanisms underlying resistance to PML-induced senescence. Here, we report that activation of the cyclin-dependent kinases CDK4 and CDK6 are essential and sufficient to impair senescence induced by PML expression. Disrupting CDK function by RNA interference or pharmacological inhibition restored senescence in tumor cells and diminished their tumorigenic potential in mouse xenograft models. Complete senescence correlated with an increase in autophagy, repression of E2F target genes, and an gene expression signature of blocked DNA methylation. Accordingly, treatment of tumor cells with inhibitors of DNA methylation reversed resistance to PMLinduced senescence. Further, CDK inhibition with palbociclib promoted autophagy-dependent degradation of the DNA methyltransferase DNMT1. Lastly, we found that CDK4 interacted with and phosphorylated DNMT1 in vitro, suggesting that CDK activity is required for its stabilization. Taken together, our findings highlight a potentially valuable feature of CDK4/6 inhibitors as epigenetic modulators to facilitate activation of senescence programs in tumor cells. Cancer Res; 76(11); 3252-64. Ó2016 AACR.
Introduction
PML was originally identified as the target of chromosome translocations in acute promyelocytic leukemia (APL; ref. 1) and as an important regulator of cellular senescence in response to oncogenes or short telomeres (2) (3) (4) . PML-induced senescence underlies the success of the treatment of APL with retinoic acid (5) . PML forms characteristic nuclear bodies that have been associated to its tumor suppressor functions enhancing the activities of the tumor suppressors p53 and RB and repressing the functions of the oncogenic kinase Akt (2, 6) . The ability of PML to induce senescence in primary human cells hinges on the RBdependent suppression of E2F-target genes expression (2, (7) (8) (9) .
Senescence acts as a tumor suppression mechanism early during carcinogenesis by imposing a proliferation barrier to cells expressing oncogenic mutations. In addition, senescence cells activate immune-mediated mechanisms that result in their clearance (10) . The senescence process induced by oncogenes in primary cells can be bypassed by mutations that inactivate the tumor suppressors p53, RB, or PML (10) . However, tumor cells can enter senescence after conventional chemotherapy, indicating that the program is not fully disabled (11) . Although chemotherapy-induced senescence in cancer cells share some biomarkers with the senescence response of primary cells, it is not yet clear whether its outcome is equally effective. In particular, it is still unknown how the multiple genetic and epigenetic changes present in tumor cells affect the efficacy of the senescence program in terms of the stability of the cell-cycle arrest and the recruitment of an effective antitumor immune response.
Our current ability to study tumor cell senescence is limited by the still poor understanding of the senescence process and the lack of definitive, reliable biomarkers. The senescence-associated b-galactosidase (SA-b-Gal), the most used senescence marker, is in fact a lysosomal enzyme (12) whose activity is increased due to a general activation of autophagy in senescent cells (13, 14) . In immortalized cells, oncogenic ras can induce several senescence biomarkers without causing a complete growth arrest. This process, called senescence with incomplete growth arrest or SWING (15) , suggests that there is more than one phenotype associated to what we call today cellular senescence. The phenomenon of senescent cell clearance in vivo may circumvent the requirement for a tight growth arrest to achieve tumor suppression. However, senescent cells in benign tumors can persist for years without progression to malignant lesions (16) , indicating that blocking cell-cycle progression is an important part of the senescent tumor suppression mechanism. Several studies indicate that the tumor suppressors RB and PML control the reversibility of the senescence program by regulating the repression of E2F target genes (8, (17) (18) (19) . In some cell types, this process involves the formation of heterochromatin structures known as senescence-associated heterochromatin foci or SAHF (20) . SAHF require high mobility group A (HMGA) proteins (21) and histone-modifying enzymes that catalyze the introduction of heterochromatin marks (22) . However, SAHF are not universal biomarkers of senescence and the heterochromatin modifications associated with them may also play a role protecting tumor cells from DNA damage signaling (23) . It is thus clear that other regulatory layers remain to be identified to understand gene expression control in senescent cells.
Here, we investigate the mechanism of resistance of tumor cells to PML-induced senescence. We first found that expression of CDK4 and CDK6 kinases inhibited PML-induced senescence in normal cells. In tumor cells, where these kinases are deregulated, PML induced an incomplete senescence program, which was restored by knockdown of CDK4 and CDK6 or expression of the CDK inhibitors p21 or p16INK4a. The CDK inhibitors flavopiridol or palbociclib (PD0332991) also increased the ability of PML to regulate tumor cell senescence in culture and reduced tumor progression in vivo. Transcriptome analysis of cells expressing PML and treated with palbociclib showed that senescence correlated with a better repression of E2F target genes and unexpectedly with a gene expression signature previously described in cells exposed to a DNA methylation inhibitor. Inhibition of DNA methylation restored the full senescence response to PML in tumor cells. CDK inhibitors acted on this pathway by promoting the autophagy-dependent degradation of DNMT1. Conversely CDK4/6 interact with and phosphorylate DNMT1 increasing its stability. Together, the results indicate that CDK4/6 kinases maintain an epigenetic mechanism that protect tumor cells from senescence and provide a proof of concept for a senescence therapy of cancer using CDK4/6 inhibitors.
Materials and Methods
Cells, retroviral gene transfer, plasmids, and reagents PC3, U2OS, HEK-293T, and normal human diploid fibroblasts IMR90 cells were obtained from ATCC. Phoenix ampho packaging cells were a gift from (S.W. Lowe, Memorial Sloan Kettering Cancer Center, New York, NY). PC3 cells were cultured in RPMI medium (Wisent) supplemented with 10% FBS (Wisent), 1% penicillin/streptomycin sulfate (Wisent), and 2 mmol/L L-glutamine (Wisent). All other cell lines were culture in DMEM (Wisent) supplemented with 10% FBS and 1% penicillin/streptomycin sulfate. Retroviral-mediated gene transfer, growth curves, and SA-b-Gal activity were assayed as described in ref. 2 .
Retroviruses pLPC, pLPC-PML, pWZL, and pWZL-PML (isoform IV) were described in ref. 2. pBABE-CDK4 and pBABE-CDK6 were a gift from S.W. Lowe. Retroviral vectors for WZL-CDK4 wildtype and K35M mutant were a gift from G.J. Hannon (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY). Flag variants for CDK overexpression of CDK2(WT), CDK4(WT), and mutant K35M were PCR amplified with a primer containing the 3xFLAG tag and subcloned in BamHI/EcoRI restriction sites to create pBABE-3xFLAG-CDK2(WT), pBABE-3xFLAG-CDK4(WT), and pBABE-3xFLAG-CDK4mut(K35M). Retrovirus pLPC-3xFLAG was described in ref. 8 . pcDNA3-Myc-DNMT1 was purchased from Addgene. Retroviral vectors with shRNAs against RB or the RB pocket proteins were also obtained from S.W. Lowe and described in ref. 18 . CDK4 and/or 6 shRNAs were cloned in retroviral vectors pMLP (MSCV-based vector expressing shRNA in a miR30 context) or pMLPX (24) . shRNA mature sequences are mentioned in Supplementary Material. pBABE-ER vector was a gift from S.W. Lowe and PML (isoform IV) was obtained by PCR from pLPC-PML (2) and subcloned between BamHI/XhoI restriction sites to create pBABE-PML IV -ER.
The CDK inhibitor flavopiridol was purchased from Selleckchem. Palbociclib (PD0332991), 5-Aza-2 0 -deoxycytidine (5-Aza-dC),
OHT (4-hydroxytamoxifen), and bafilomycin A1 were purchased from Sigma-Aldrich. Treatments at the indicated concentrations with flavopiridol, palbociclib, and OHT were renewed every 3 days and 5-Aza-dC was added once for three days.
Immunoblotting and immunofluorescence
Protein expression analysis was performed as described in ref. 8 . Antibodies, immunoprecipitation protocol, and in vitro protein kinase assays are described in Supplementary Materials and Methods. For immunofluorescence studies, cultured cells were plated on coverslips and fixed as described in ref. 8 . For LC3B and p62 immunodetection, cells were treated 24 hours with bafilomycin A1 (50 nmol/L) prior to fixation. The primary antibodies used were: anti-53BP1 rabbit polyclonal (1:200, EMD Millipore #PC712), anti-DNMT1 rabbit polyclonal (1:200, Cell Signaling Technology, #5032), anti-PML mouse monoclonal (1:400, Santa Cruz Biotechnology PG-M3), anti-LC3B rabbit polyclonal (1:400, Cell Signaling Technology, #2775), or anti-SQSTM1/p62 rabbit polyclonal (1:400, Cell Signaling Technology, #5114). Secondary antibody combinations used were: AlexaFluor 488 goat anti-mouse and Alexa-Fluor 568 goat anti-rabbit (1/2000, Molecular Probes, Invitrogen). We used as mounting media ProLong Gold Antifade Reagent with DAPI (Invitrogen). Images were collected on an upright microscope Axio Imager.Z2 (Zeiss) with the Zen Microscope and imaging software.
Animals
Mouse experiments were conducted in accordance with institutional and national guidelines and regulations. For xenografts, 30 BALB/c 6-week-old nude mice (Charles River) were injected subcutaneously in both flanks with 10 6 PC3 cells expressing empty vector (V) or PML. Cells were suspended in PBS mixed with Matrigel (BD Biosciences). Tumor formation was followed every 2 days for a period of 18 days. When tumors reached around 150 mm 3 , mice were separated in three treatment groups for each condition: NT, nontreated (control); Fl, flavopiridol (5 mg/kg/ day diluted in 0.9% NaCl-0.1% DMSO injected intraperitoneally); Pa, palbociclib (PD 0332991: 100 mg/kg/day diluted in sodium lactate 50 mmol/L pH 4 administered by gavage).
Mice were treated for 5 consecutive days. Tumor growth was measured every 2 days for the following 22 days without further treatments. Statistical analysis was performed using SPSS software 16.0 (SPSS, Inc.). The nonparametric Kruskal-Wallis test was used to show significant differences in tumor growth among groups. All values were expressed as mean (AE SE of the mean; SEM). A P value of less than 0.05 was accepted as statistically significant. Mice were euthanized before the endpoint of the experiment when tumor volume reached 2 cm 3 . Tumors were collected and either snap frozen (for later RNA extractions) or fixed in 10% neutral-buffered formalin solution, paraffin embedded, and cut into sections for immunofluorescence analysis.
Immunofluorescence from paraffin-embedded samples
Tumor sections from xenografts were deparaffinized and rehydrated. Antigen epitope retrieval was performed by heating for 25 minutes at 95 C in sodium citrate buffer (10 mmol/L sodium citrate, 0.05% Tween 20, pH 6.0). Samples were permeabilized with Triton 0.5%-PBS 1X solution for 15 minutes and blocked with 3% BSA, 5% goat serum, 0.1% Tween 20-PBS 1X solution for 1 hour. Samples were incubated with the primary antibody at 4 C overnight as follows: anti-PML (mouse monoclonal, PG-M3 SC966; Santa Cruz Biotechnology; 1:400); anti-LC3B (rabbit polyclonal, 2775S; Cell Signaling Technology; 1:400); anti-SQSTM1/p62 (rabbit polyclonal, 5114; Cell Signaling Technology; 1:400). The next day, samples were washed in PBS 1X and incubated with goat anti-mouse AlexaFluor 488 (1:1,000; A-11029, Molecular Probes, Invitrogen) or anti-rabbit AlexaFluor 568 (1:1,000; A-11036, Molecular Probes, Invitrogen). For mounting, we used ProLong Gold Antifade Reagent with DAPI (P36931; Invitrogen).
RNA expression analysis
Snap-frozen tumor samples were transferred to RLT buffer (Qiagen) for homogenization first with micropestels and then by passing the samples through QIAshredder column (Qiagen) prior to RNA isolation with RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions. Cultured cells were collected in TRIzol reagent (Invitrogen) for RNA extractions, according to the manufacturer's instructions and RNA samples sent for gene arrays (Human Gene 2.0 ST Array, at the McGill University and G enome Quebec Innovation Center, Montreal, Quebec, Canada) were further purified with RNeasy MinElute Cleanup Kit (Qiagen).
The microarray data files from triplicates of the four conditions were analyzed with the Affymetrix Expression Console Software and Transcriptome Analysis Console (www.affymetrix.com). Raw data were normalized with a Robust Multi-array Average (RMA) algorithm. The microarray data were deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO Series accession number GSE70923.
The gene set enrichment analysis (GSEA) software was used to match gene expression patterns in our four conditions with gene sets available in the Molecular Signature Database (MSigDB). The significance of enrichment values (NES) was determined by the false discovery rate (FDR; q value) and by a nominal P value calculated by an empirical phenotype-based permutation test procedure as described previously (25) . Only enriched gene sets with a P value 0.05 and a q value 0.25 were considered significant. A detailed explanation of our bioinformatic analysis was previously published in ref. 26 .
Quantitative real-time PCR was performed as described in ref. 8 . Primer sequences are available in Supplementary Material and Methods.
Results

Expression of cyclin-dependent kinases CDK4 and CDK6 suppresses PML-induced senescence
To investigate the mechanisms allowing tumor cells to evade senescence, we first tested whether expression of the kinases CDK4 and CDK6 could prevent PML-induced senescence in normal human fibroblasts. We found that these kinases efficiently blocked PML-induced growth arrest and senescence in normal cells ( Fig. 1A and Supplementary Fig. S1A-S1C ). One important function of PML during senescence involves RB and the repression of E2F target genes (8) . Accordingly, the expression of CDK4 or CDK6 was able to restore the expression of multiple E2F targets in PML-expressing cells ( Supplementary Fig. S1D ). In a similar way, RB knockdown but not p107 or p130 knockdown suppressed PML-induced senescence and increased the expression of E2F target genes ( Supplementary Fig. S1E -S1H). Together, these experiments indicate that expression of CDK4 or CDK6 beyond a certain threshold can overcome the ability of PML to engage the RB pathway and induce senescence in normal cells.
As cancer cells have defects in the RB pathway, we anticipated that PML could induce a better senescence response in tumor cells if the functionality of the RB pathway is strengthened. Thus, to investigate whether CDK inhibition could improve the ability of PML to inhibit the growth of tumor cells, we co-expressed PML with shRNAs against CDK4, CDK6, or a construct expressing shRNAs simultaneously against CDK4 and CDK6. In U2OS cells, PML reduced cell growth but shRNAs against CDK4 or CDK6 did not. Combining shCDK4 and shCDK6 slightly reduced cell growth but in combination with PML expression, we observed a stronger growth reduction (Fig. 1B) . In PC3 prostate cancer cells, PML also inhibited cell growth and this effect was enhanced by coexpressing shRNAs against CDK4 or 6 and even more when both shRNAs were coexpressed (Fig. 1C ). shCDK4 and shCDK6 efficiently reduced the levels of their targets when used alone or when expressed together in the same vector (Fig. 1D) . We also assessed RB levels in U2OS cells expressing PML and the different shRNAs. RB levels in senescent cells appear reduced in Western blots ( Fig. 1D ; ref. 7) . Another hallmark of senescence is the accumulation of DNA damage foci, which we measured with antibodies against the DNA damage response protein p53BP1. Downregulation of CDK4/6 with shRNAs (two different combinations of shRNAs against CDK4 and CDK6) increased the number of U2OS cells with several p53BP1 foci and expression of PML further increased the number of these foci (Fig. 1E) . Senescence is also characterized by an increase in autophagy markers (13) . The lipid-conjugated form of LC3 known as LC3B accumulates in senescent cells when the autophagy flux is inhibited with vacuole ATPase inhibitors such as bafilomycin A1 (13) . We found that cells expressing PML and shRNAs against CDK4/6 accumulate the autophagy markers LC3B and p62 (Fig. 1F ). This is best illustrated using single-cell analysis by immunofluorescence using antibodies specific for these markers. The number of cells having high numbers of LC3B and p62 foci is much higher after combining PML with shCDK4/6 ( Fig. 1G and H). To confirm our shRNA results, we next inhibited CDKs by forcing the expression of the CKIs p21 and p16INK4A (Supplementary Fig. S2A and S2B). Both p21 and p16INK4A expression inhibited the growth of U2OS ( Supplementary Fig. S2C ) and PC3 cells ( Supplementary  Fig. S2D ) and cooperated with PML to further inhibit cell growth.
Next, we tested whether pharmacologic inhibitors of CDKs also cooperated with PML to reduce cancer cell proliferation. We used flavopiridol, a drug that inhibits several CDKs (27) and palbociclib (PD0332991), a selective and potent inhibitor of CDK4 and CDK6 (28) . In PC3 cells, the combination flavopiridol-PML was slightly better than PML alone to reduce cell growth ( Fig. 2A ) and induce senescence (Fig. 2C ). In contrast, combining palbociclib with PML was dramatically more effective ( Fig. 2B and C) . The autophagy/senescence markers LC3B and p62 accumulated at higher levels in cells expressing PML and treated with the CDK inhibitors ( Fig. 2D-F) . Similar results were obtained in U2OS cells ( Supplementary Fig. S3 ). These results are consistent with the idea that CDK inhibitors potentiate the senescence tumor-suppressive functions of PML.
To obtain in vivo evidence that CDK inhibitors and PML cooperate in tumor suppression, we prepared PC3 cells expressing PML or a vector control and injected them in the flanks of nude mice. The animals were then divided in six groups each with 5 animals injected in each flank. CDK4/6 kinases suppress PML-induced senescence. A, cell growth estimated from a crystal violet retention assay of IMR90 cells expressing PML together with a vector control (V), CDK4 or CDK6. B, relative growth of U2OS cells infected with empty vector (V) or a vector-expressing PML (P) as well as a vector expressing either a control nontargeting shRNA (shNTC), an shRNA against CDK4 (shCDK4), CDK6 (shCDK6), or two shRNAs targeting CDK4 and CDK6 (shCDK4/6). C, relative growth of PC3 cells modified as in B. D, immunoblots against the indicated proteins using U2OS cells as in B. E, quantification of DNA damage foci per cells after indirect immunofluorescence for 53BP1 in IMR90 cells infected with control vector (normal) or oncogenic Ras (senescent) and in U2OS cells bearing an empty vector (V) or PML and further modified with a control nontargeting shRNA (shNTC), or double shRNAs, shCDK4/6-1 and shCDK4/6-2 (sh1 or sh2). F, immunoblots against the indicated proteins using U2OS cells as in E. G, fluorescent imaging of LC3B and p62 foci as markers of autophagy (red) of U2OS cells as in E and treated with 50 nmol/L bafilomycin A1 for 24 hours. PML staining is shown in green and nuclear DNA (DAPI) in blue. Scale bar, 10 mm. H, quantification of LC3B and p62 foci per cells using data from multiple immunofluorescence images as in G. Cells presenting more than 100 foci were considered positive for induction of autophagy. Three sets of 100 cells were looked at. Error bars, mean AE SD, Ã , P < 0.05; ÃÃ , P < 0.01; and ÃÃÃ , P < 0.005 using Student t test. Error bars, mean AE SD, Ã , P < 0.05; ÃÃ , P < 0.01; and ÃÃÃ , P < 0.005 using Student t test. C, SA-b-Gal in PC3 cells infected with empty vector (V) or a vector-expressing PML treated with vehicle (Ctrl), 120 nmol/L flavopiridol (Fla), or 500 nmol/L palbociclib (Pal). D, immunoblots for the indicated proteins in cells as in C. TUB, tubulin E, LC3B and p62 foci (red) visualized after immunofluorescence staining of PC3 cells as in C. PML staining is shown in green and nuclear DNA (DAPI) in blue. Scale bar, 10 mm. F, quantification of LC3B and p62 foci per cells of immunofluorescence performed in E. Cells presenting more than 100 foci were considered positive for induction of autophagy. Three sets of 100 cells were looked at. Error bars, mean AE SD, Ã , P < 0.05; ÃÃ , P < 0.01; and ÃÃÃ , P < 0.005 using Student t test.
expressed PML and were also treated for five days with vehicle (PML/NT), flavopiridol (PML/Fl), or palbociclib (PML/Pa). Tumors with an empty vector or PML progressed without treatment, although PML moderately reduced tumor growth. Treatment with CDK inhibitors reduced tumor growth but the best results were obtained in PML-expressing tumors after treatment with either flavopiridol or palbociclib (Fig. 3A-C) . In fact, the combination of PML and CDK inhibitors completely eliminated the tumors in some animals, suggesting either tumor cell death or clearance by the innate immune system. Of note, all tumors recovered from PC3-PML had a reduction in the expression level of retroviral transcripts (Fig. 3D) , suggesting a preferential growth in vivo of cells with less transcription of the expression vector and explaining why in some animals the treatment did not totally eliminate the tumors. As shown previously with cells in culture, the combination of PML with CDK inhibitors induced a higher accumulation of the autophagy markers LC3B and p62 when analyzed several days after the treatment was stopped (Fig. 3E and F).
Gene expression profile of cells expressing PML and treated with CDK inhibitors
We next compared the transcriptome of PC3 cells expressing PML or a vector control and treated with palbociclib or vehicle. The comparisons of control cells with cells expressing PML or treated with palbociclib are described in the Supplementary Fig.  S4 . In general, both PML and palbociclib regulate cell cycle, E2F targets, and interferon genes although obviously these changes were not sufficient to trigger a stable senescence response. Next, we compared senescent cells (PML-expressing and palbociclib-treated PC3 cells), with either PC3 cells expressing a vector control treated with palbociclib or PC3 cells expressing PML but not treated with palbociclib ( Supplementary Fig. S5 ). These evaluations are expected to reveal the critical gene expression changes associated to stable senescence, especially those that are common to both comparisons. One hallmark of senescence is the upregulation of genes involved in inflammation and the immune response (29) . Consistent with the senescence phenotype induced by the combination of PML and palbociclib, several cytokine genes were found upregulated in this condition in comparison with cells expressing PML alone or cells treated with palbociclib ( Supplementary Fig. S5A and S5B ). Another characteristic of senescent cells is the downregulation of E2F target genes (8, 18) . As mentioned above, both PML and palbociclib when used alone induced a downregulation of several E2F targets in PC3 cells ( Supplementary Fig. S4D and S4H) but their combination was even more effective, increasing the number of E2F targets that are downregulated ( Supplementary Fig. S5C and S5D) . Intriguingly, we found a downregulation of several E2F target genes that play a role in DNA repair in cells treated with PML and palbociclib ( Supplementary Fig. S5E and S5F ). This is consistent with previous findings during PML-induced senescence in primary fibroblasts (8), suggesting a mechanism to explain the persistent DNA damage response seen in senescent cells.
Remarkably, the gene expression pattern of PML/palbociclibtreated cells overlaps with the pattern observed in pancreatic cancer cells treated with DNA methylation inhibitors ( Fig. 4A  and B) . CDC2, CDC6, CENPF, FOXM1, LMNB1, and HMGB2, were among the genes downregulated in cells treated with DNA methylation inhibitors (30) . We confirmed their enhanced downregulation in PML/palbociclib-treated cells when compared with control growing cells expressing empty vectors, control cells treated with palbociclib, or cells expressing PML alone (Fig.  4C ). In addition, we confirmed that PML/palbociclib treatment increased the levels of several senescence-regulatory genes repressed by DNA methylation. They include EDN1 (31), GADD45A (32), IFI44L (33), IL23A (34) , and SerpinE1/PAI1 ( Fig. 4D; ref. 5) . Together, the gene expression pattern suggests that the prosenescence interaction between PML and palbociclib involves the control of DNA methylation.
DNA methylation and DNMT1 control tumor cells resistance to senescence
To investigate whether gene regulation due to DNA methylation plays a role in the resistance of tumor cells to PML-induced senescence, we treated PC3 prostate cancer cells with the DNA methyl transferase inhibitor 5-aza-2 0 deoxycytidine (5-Aza-dC). The drug decreased cell growth in control cells but the effect was more pronounced when combined with PML expression (Fig.  5A) . Hence, DNA methylation inhibitors, like CDK inhibitors, cooperate with PML to induce growth arrest. Next we investigated whether 5-Aza-dC cooperated with PML to induce senescence. Treatment of PC3 cells with 5-Aza-dC at doses between 40 and 250 nmol/L only slightly induced SA-b-Gal activity, similar to PML expression alone. However, combining PML expression with the drug induced a dose-dependent SA-b-Gal activity in these cells (Fig. 5B) . Similar results were found when using autophagy markers LC3B and p62, which were both more abundant in cells treated with 5-Aza-dC and expressing PML (Fig. 5C and D) .
To further confirm that PML and 5-Aza-dC cooperate to induce senescence we prepared PC3 cells expressing a PML fusion protein with the ligand binding domain of the estrogen receptor (PML-ER) that is active in the presence of OHT. In normal fibroblasts expressing PML-ER, treatment with OHT for one week induced a senescent cell-cycle arrest where 96% of the cells were positive for SA-b-Gal (Supplementary Fig. S6A ). To study the reversibility of this phenotype, we treated PML-ER-expressing normal fibroblasts for 1, 2, 3, 4, and 7 days with OHT and then cultured them for another 5 days without OHT. We found that induction of PML-ER for 1 or 2 days was not sufficient to induce a lasting senescence. However, induction of PML-ER with OHT for more than 3 days led to a stable senescent phenotype (Supplementary Fig. S6B ). In contrast to normal cells, activation of PML-ER with OHT in PC3 prostate cancer cells only slightly reduced growth. Pretreatment of the cells, 6 days prior to the growth assay but not during the assay, with palbociclib or 5-Aza-dC alone moderately reduced cell growth in a dose-dependent manner ( Fig. 6A and Supplementary  Fig. S6C and S6D ). However, inducing PML activation with OHT in tumor cells that were previously exposed to palbociclib or 5-Aza-dC lead to stronger growth arrest in response to both drugs ( Fig. 6A and Supplementary Fig. S6C and S6D ). These results suggest that the effects of 5-Aza-dC or palbociclib leading to cooperation with PML to induce senescence were imprinted in the cell population because they remained after the drugs were removed. In addition, most cells exposed sequentially to palbociclib or 5-Aza-dC and PML activation were unable to proliferate even after removal of the PML-ER inducer OHT (Fig. 6B and Supplementary Fig. S6E and S6F) . Interestingly, pretreatment with palbociclib dramatically increased the growth arrest response to the chemotherapeutic drug camptothecin (Fig. 6C) , indicating that its epigenetic effects facilitate the cellular senescence response to different agents. As the cooperation between PML and palbociclib led to changes in gene expression related to inhibition of DNA methylation and the DNMT1 inhibitor 5-Aza-dC has effects on tumor cells similar to palbociclib, we next explored whether palbociclib affected DNMT1 levels. We found that palbociclib decreased DNMT1 levels in a dose-dependent manner ( Fig. 7A and Supplementary  Fig. S7A ). Of note, it has been reported that CDK1 and CDK2 phosphorylate DNMT1 at serine 154 stabilizing the protein (35) . Using a phosphospecific antibody for this modification, we found that the levels of DNMT1 phosphorylated at serine 154 correlated with the levels of the total DNMT1 (Fig. 7A) . Most likely, the reduced signal with the phosphospecific antibody is due to a corresponding reduction of the total levels of DNMT1. We next confirmed that reduction of CDK4 and CDK6 with shRNAs also reduced DNMT1 levels (Fig. 7B) , suggesting that the effect of palbociclib is due to inhibition of these kinases and not an off target effect of the compound. Conversely, overexpression of CDK4 or CDK6 but not CDK2 dramatically increased DNMT1 levels in normal human fibroblasts (Fig. 7C ). This effect of CDK4 or CDK6 on DNMT1 was not observed at the mRNA level (Fig.  7D) , indicating an effect on translation or protein stability. The proteasome inhibitor MG132 was not able to rescue the levels of DNMT1 in palbociclib-treated cells (Fig. 7E) . In contrast, the autophagy inhibitor bafilomycin A1 stabilized DNMT1 in palbociclib-treated cells (Fig. 7F) . Taken together, these results are consistent with a model where CDK4 and CDK6 protect DNMT1 from autophagy-dependent protein degradation.
To investigate whether CDK4 can directly regulate DNMT1, we immunoprecipitated a flag-tagged allele of CDK4 expressed in HEK-293T cells with a Myc-tagged allele of DNMT1. We found DNMT1, after immunoblotting the CDK4 immunoprecipitates (Fig. 7G) , suggesting a protein-protein interaction. Next, we used purified CDK4/cyclin D to assay for kinase activity on purified GST-DNMT1. We observed that CDK4/cyclin D phosphorylated DNMT1 in vitro (Fig. 7H) . Finally, we used gel-purified GST-DNMT1 previously incubated with CDK4/cyclin D under kinase assay conditions to analyze the phosphorylation sites using mass spectrometry. We found that CDK4/cyclin D phosphorylated DNMT1 at serines 127 and 954 ( Fig. 7I and Supplementary Fig.  S7B ). It has been reported that AKT can phosphorylate DNMT1 at serine 127 (36); however, this site fits better the consensus of a proline-directed kinase such as the CDKs. We found a single peptide phosphorylated at serine 247 but as this site does not fit the consensus of a proline-directed kinase we think it is not a relevant CDK4 phosphorylation site. Phosphorylation of DNMT1 at serine 954 has never been reported, but the site is close to a cluster of acetylation sites controlled by SirT1 (37) , suggesting that these two modifications may functionally interact. Together, the results support a model where CDK4/6 regulate DNMT1 stability via its phosphorylation although it is also possible that these kinases may affect the autophagy program as well.
Discussion
Cellular senescence is a very efficient mechanism to prevent tumorigenesis that is triggered in normal cells after activation of oncogenes or a mitotic stress leading to telomere shortening (10) . We show here that human cancer cells are resistant to PMLinduced senescence due to hyperactive CDK4/6 signaling and that decreasing the activity of these kinases can restore the senescence response to PML activation. We found that CDK4/6 kinases control the phosphorylation and stability of DNMT1, which is required to maintain an epigenetic mechanism that prevents PMLand chemotherapy-induced senescence. The epigenetic marks maintained by DNMT1 in tumor cells to prevent senescence can act by several mechanisms including repression of prosenescence antiproliferative genes, enhancement of gene repression by RB-E2F complexes, and the control of genome stability. Our data supports these three nonexclusive possibilities. First, we identified several candidate tumor suppressors reexpressed in PC3 prostate cancer cells expressing PML and treated with the CDK4/6 inhibitor palbociclib. These genes were previously shown to be controlled by DNA methylation and include SerpinE1 (5, 38) , IL23A (34), GKN2 (39), IGFBP3 (40) , TNFAIP3 (41), IFI44L (33), SSX (42), EDN1 (31) , and GADD45A (43) . Consistent with this idea, it has been reported that DNA methylation inhibitors promote the expression of interferon target genes (30), many of which are known to play a role in senescence (44) . Second, several E2F target genes were better repressed by the combination of PML and palbociclib (Fig.  5C ), suggesting that inhibition of DNA methylation can enhance E2F targets gene repression by RB. In support of this mechanism, it has been reported that DNA binding by E2F transcription factors is sensitive to DNA methylation (45) . Third, we found increased DNA damage signals in cells treated with palbociclib and PML, a phenomenon that can be explained by the role of DNMT1 controlling genome stability via methylation of juxtacentromeric satellite DNA (46) .
The idea that DNA methylation prevents senescence is consistent with the widespread DNA hypomethylation observed in senescence cells using large-scale DNA methylation analysis (47) . Hypomethylation in cells approaching senescence was linked to mislocalization of DNMT1 (47) , indicating that DNMT1 is a key target to reprogram the genome for senescence. We add here a new mechanism controlling DNMT1 in senescence: decreased stability due to lack of CDK4/6-dependent phosphorylation of DNMT1. In vitro, CDK4 was able to phosphorylate DNMT1 at serines 127, 243, and 954 but further work will be required to precisely determine the role of each of these phosphorylation sites in vivo. Nevertheless, inhibition of CDK4/6 activity allowed autophagy-dependent degradation of DNMT1. Autophagy plays an important role in senescence controlling the expression of inflammatory cytokines (13, 14) and the nuclear envelope protein lamin B1 (48) . We thus identified DNMT1 as a novel nuclear target of autophagy-dependent protein degradation in senescent cells. It is intriguing that lamin B1 and DNMT1 are targets for autophagydependent protein degradation and both control large-scale patterns of gene expression, suggesting that autophagy is mechanistically linked to genome reprogramming during cellular senescence.
It is still not clear how tumor cells acquire DNA methylation changes that block cellular senescence. DNMT1 is the most abundant DNA methyltransferase in cells and maintains DNA methylation patterns initially laid out by the de novo methylases DNMT3A and DNMT3B (49) . An abnormal and cancer-specific gain of DNA methylation at promoters of tumor suppressor genes would require a mechanism to recruit de novo methylases to these promoters. Alternative, DNA methylation of tumor suppressors mediating senescence can be part of a normal mechanism that ensures self-renewal in stem cells and that requires DNMT1 for its maintenance. Consistent with this idea, DNMT1 is normally required to maintain populations of progenitor cells and prevent their exhaustion by cell differentiation (50) . Reactivation of this program in tumor cells can explain why they acquire antisenescence epigenetic marks and drugs that can revert it should be promising for cancer therapeutics.
CDK4/6 inhibitors were conceived as cell-cycle inhibitors and are in clinical trials for the treatment of breast cancer and other malignancies (51) . Our results linking this drug family to the control of epigenetic programs is unexpected and may justify their use beyond cell-cycle control. It is plausible that in addition to their cell-cycle effects their clinical efficacy is related to their ability to inactivate DNMT1 and sensitize cells for irreversible senescent cell-cycle arrest (Fig. 7J) . Our results showing cooperation between CDK4/6 inhibitors and the senescence regulator PML may also indicate that PML status in tumors can predict the response to these drugs. It has been recognized that chemotherapeutic agents can induce tumor cell senescence (11) and CDK4/6 inhibitors can enhance this response acting as erasers of tumor epigenetic marks. Likely, these drugs could be widely used to improve the effect of a variety of chemotherapeutic agents.
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